Cell Line-Derived Xenograft (CDX) Models
Cell line-derived xenograft (CDX) models have revolutionized the field of cancer research and drug development. These models provide a robust platform for preclinical testing, enabling the evaluation of test compounds' efficacy, toxicity, and overall therapeutic potential. The ease and shorter timelines involved in CDX studies allow for efficient screening of test compounds, accelerating the drug discovery process. Our company, with its expertise in CDX model development, is committed to advancing cancer research and translating scientific discoveries into effective rare disease drug development.
Introduction to CDX Models
Cell line-derived xenograft (CDX) models involve the transplantation of human tumor cell lines into immunodeficient animal hosts, typically mice, to study tumor development and evaluate the efficacy of potential therapeutics. CDX models are commonly conducted in immuno-deficient animals, such as Nude, SCID, NSG, and NRG strains of mice. These animals lack functional immune systems, allowing the growth of human cancer cells without interference from the host's immune response. By using immuno-deficient mice, researchers can exclusively focus on studying the tumor development and therapeutic effects of test compounds in mitigating the disease.
Fig.1 Animal models in lung cancer. (Karakurt, Serdar, et al., 2023)Types of CDX Models
- Subcutaneous CDX Models
The subcutaneous CDX model is a widely utilized approach in tumorigenesis research, where tumor cells are implanted in the subcutaneous area of nude mice, typically in the armpit or the back of the forelimb. One of the key advantages of the subcutaneous CDX model is its simplicity and ease of operation. The implantation procedure is straightforward, allowing for direct observation of tumor growth throughout the study.
- Orthotopic CDX Models
The orthotopic CDX model involves the implantation of tumor cell lines directly into the in situ organs or tissues of mice to establish a tumor-bearing model. By implanting tumor cells in their anatomically correct location, this model provides a more accurate representation of the native tumor microenvironment, including interactions with surrounding cells, extracellular matrix, and blood vessels.
Our Services
Our company offers expert assistance in generating CDX models tailored to your specific rare disease research needs. To ensure the reliability and relevance of CDX models, we provide thorough characterization and validation services. We employ various techniques, including histopathological analysis, molecular profiling, and immune cell infiltration assessment, to validate the presence and behavior of tumor cells within the CDX model. In addition, we offer drug safety evaluation and pharmacokinetics research using CDX models to assess the absorption, distribution, metabolism, and excretion (ADME) properties of test compounds.
Recipient Backgrounds: NOD SCID, BALB/c nude, C-NKG mice.
Typical Injection Sites: intravenous, subcutaneous, or in situ.
Available Cell Lines:
| Bladder | T24/83, RT112/84, UM-UC-3, J82, HT1197, KU-19-19, VM-CUB1 | Liver | BEL-7404, Hep3B, Huh 7, HepG2, SNU-182, QGY7703, SNU-398, JHH-7, MHCC97H, SK-HEP-1 |
| Brain | Brain (5) U87, LN-229, D283, T98G, U118MG | Lung (Small cell) | NCI-H69, NCI-H1417, NCI-H446, NCI-H526, NCI-H82, SHP-77, DMS114, NCI-H211, NCI-H209, NCI-H2286 |
| Neuroblastoma | CHP-134, SK-N-AS, BE (2)-C, SH-SY5Y | Melanoma | A375, SK-MEL-24, SK-MEL-28, COLO 829, SKMEL-5 , MDA-MB-435S, MeWo |
| Sarcoma | HT1080, A673, KHOS/NP, 143B, SJSA-1, SAOS-2, A204, G401, Aska-SS, HS-SY-II, Yamato-SS | Myeloma | KMS-28BM, KMS-11, MOLP-8, NCI-H929, RPMI 8226, MM.1S, OPM-2 |
| Colorectal | Colo205, HT29, HCT-116, HCT-15, LS180, LS174T, SW620, HT55, DLD-1, Lovo, COLO-320DM, RKO, Caco-2, T84, WiDr, SW480, SW 48, LS411N, COLO 201 | Breast | Cal51, BT-474, HCC1954, MDA-MB-231, MDAMB-468, HCC1806, MCF7, HCC1937, MDA-MB-436, SUM-52PE, JIMT-1, MDA-MB-361, SUM 159PT, MFM-223, T47D, HCC1428, ZR-75-1, MT-3, DU4475 |
| Duodenal | HuTu80 | Esophageal | T.Tn, OE21 |
| Ovary | A2780, SK-OV-3, ES-2, OVCAR-3, TOV21G | Pancreas | BxPC3, Mia-pa-ca-2, KP4, PANC-1, CAPAN-1, Panc 02.13, AsPC-1, HPAC, HPAFI |
| Gastric | NUGC4, SNU-1, SNU-16, MGC-803, SNU5, MKN45, HS 746T | Prostate | PC-3, DU145, LNCap, VCaP, 22RV.1 |
| Head & Neck | Cal 27, RPMI2650, SCC-9, Fadu | Renal | 786-O, ACHN, Caki-1, SK-NEP-1, A498 |
| Skin | A431 | Cervical | SW756, Ca Ski |
| Lymphoma | Daudi, SU-DHL-2, SU-DHL-4, SU-DHL-6, SU-DHL-10, Granta-519, Maver-1, Mino, NAMALWA, Raji, Ramos, RL, Z-138, U937, DoHH2, Farage, Pfeiffer, REC-1, U2932, Toledo | Leukemia | HEL 92.1.7, MV4-11, CCRF-CEM, HL-60, K562, KG1, MOLT-4, Kasumi-1, Nalm-6, THP-1, SET-2, PL-21, MKL-1 |
| Testicular Embryonal | NEC14 | Thyroid | TT |
| Lung | NCI-H1650, NCI-H226, NCI-H460, PC9, A549, Calu-1, Calu-6, EBC-1, A427, NCI-H647, MSTO211H, NCI-H292, NCI- H322, NCI-H358, NCI-H441, NCI-H520, NCI-H1975, NCI-H2228, SK-MES-1, HCC4006, NCI-H1703, NCI-H727, NCI-H2122, DV-90, NCI-H69, NCI-H1417, NCI-H446, NCI-H526, NCI-H82, SHP77 , Calu-3, NCI-H2170, NCI-H820, NCI-H23, NCI-H1568, NCI-H1944, NCI-H2023, NCI-H2030, NCI-H2126, NCI-H838, NCI-H1838, DMS114, NCI-H211, NCI-H209, NCI-H2286, NCI-H596 | ||
Why Choose Us?
As a company specializing in the research and development of therapies for rare diseases. We offer our valued customers a solution that is both cost-effective and convenient. Our service involves developing cell line-derived xenograft (CDX) models, which helps to streamline the workflow. This is done by a dedicated team of highly trained scientists who utilize our advanced platform to provide exceptional services and deliver high-quality products tailored to meet each customer's unique requirements. If you are interested in our services, please feel free to contact us for more details and quotation information of related services.
Reference
- Karakurt, Serdar, et al. "Animal Model of Human Cancer: Malignant Lymphoma/Colon Cancer/Lung Cancer/Liver Cancer/Brain Tumors/Skin Cancer." Handbook of Animal Models and its Uses in Cancer Research. Singapore: Springer Nature Singapore, 2023. 223-246.
All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.